Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Giesel, Frederik L. [VerfasserIn]   i
 Will, Leon [VerfasserIn]   i
 Kratochwil, Clemens [VerfasserIn]   i
 Haberkorn, Uwe [VerfasserIn]   i
Titel:Intra-individual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma
Titelzusatz:a pilot study
Verf.angabe:Frederik Giesel, Leon Will, Ismaheel Lawal, Thabo Lengana, Clemens Kratochwil, Mariza Vorster, Oliver Neels, Florette Reyneke, Uwe Haberkon, Klaus Kopka, and Mike Sathekge
Jahr:2018
Umfang:5 S.
Fussnoten:Published online: December 21, 2017 ; Im Titel falsche Schreibweise von Uwe Haberkorn ; Im Titel ist "18" hochgestellt ; Gesehen am 21.06.2018
Titel Quelle:Enthalten in: Journal of nuclear medicine technology
Ort Quelle:New York, NY : Soc., 1973
Jahr Quelle:2018
Band/Heft Quelle:59(2018), 7, Seite 1076-1080
ISSN Quelle:1535-5675
Abstract:Introduction: The introduction of 18F-labelled prostate-specific membrane antigen (PSMA) targeted positron emission tomography/computed-tomography (PET/CT) tracers, firstly 18F-DCFPyL and more recently 18F-PSMA-1007, have demonstrated promising results for the diagnostic workup of prostate cancer (PCa). This clinical study presents an intra-individual comparison to evaluate tracer-specific characteristics of 18F-DCFPyL versus 18F-PSMA-1007. Methods: Twelve prostate cancer patients, drug naive or prior to surgery, received similar activities of about 250 MBq 18F-DCFPyL and 18F-PSMA-1007 48 h apart and were imaged 2 h p.i. in the same PET/CT-scanner using the same reconstruction-algorithm. Normal organ biodistribution and tumor uptakes were quantified using SUVmax. Results: PSMA-positive lesions were detected in twelve out of twelve PCa patients. Both tracers, 18F-DCFPyL and 18F-PSMA-1007, detected the identical lesions. No statistical significance could be observed when comparing the SUVmax of 18F-DCFPyL and 18F-PSMA-1007 for local tumor, lymph node metastases and bone metastases. With regard to normal organs, 18F-DCFPyL presented statistically significant higher uptake in kidneys, urinary bladder and lacrimal gland. Vice versa, significantly higher uptake of 18F-PSMA-1007 in muscle, submandibular and sublingual gland, spleen, pancreas, liver and gallbladder was observed. Conclusion: Excellent imaging quality was achieved with both 18F-DCFPyL and 18F-PSMA-1007 resulting in identical clinical findings for the evaluated routine situations. Non-urinary excretion of 18F-PSMA-1007 might present some advantage with regard to delineation of local recurrence or pelvic lymph-node metastasis in selective patients; the lower hepatic background might favor 18F-DCFPyL in very late stages when rare cases of liver metastases can occur.
DOI:doi:10.2967/jnumed.117.204669
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: http://dx.doi.org/10.2967/jnumed.117.204669
 Volltext: http://jnm.snmjournals.org/content/early/2017/12/20/jnumed.117.204669
 DOI: https://doi.org/10.2967/jnumed.117.204669
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:18F-DCFPyL
 18F-PSMA-1007
 Molecular Imaging
 Oncology: GU
 PET/CT
 Prostate carcinoma
 PSMA
K10plus-PPN:157644404X
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68262313   QR-Code
zum Seitenanfang